and Immunology/dr_raghu/new... · characterized by a primary or secondary deficit in cellular and...
4
Transcript of and Immunology/dr_raghu/new... · characterized by a primary or secondary deficit in cellular and...
![Page 1: and Immunology/dr_raghu/new... · characterized by a primary or secondary deficit in cellular and humoral immune mechanisms. The oncogenic potential of multimodality therapy might](https://reader033.fdocuments.net/reader033/viewer/2022042005/5e6fa72496c9e0651d683699/html5/thumbnails/1.jpg)
![Page 2: and Immunology/dr_raghu/new... · characterized by a primary or secondary deficit in cellular and humoral immune mechanisms. The oncogenic potential of multimodality therapy might](https://reader033.fdocuments.net/reader033/viewer/2022042005/5e6fa72496c9e0651d683699/html5/thumbnails/2.jpg)
![Page 3: and Immunology/dr_raghu/new... · characterized by a primary or secondary deficit in cellular and humoral immune mechanisms. The oncogenic potential of multimodality therapy might](https://reader033.fdocuments.net/reader033/viewer/2022042005/5e6fa72496c9e0651d683699/html5/thumbnails/3.jpg)
![Page 4: and Immunology/dr_raghu/new... · characterized by a primary or secondary deficit in cellular and humoral immune mechanisms. The oncogenic potential of multimodality therapy might](https://reader033.fdocuments.net/reader033/viewer/2022042005/5e6fa72496c9e0651d683699/html5/thumbnails/4.jpg)